{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 41,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a waterfall plot to visualize tumor shrinkage (Best % Change in SPD) across different patient performance status cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/11",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.35,
        "y": 0.15
      },
      "kind": "chart",
      "text": "ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline Glioma",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "768d209e-44aa-4e71-b9bc-d8b879ecc5fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "100: 1/2 (50%)\n90: 4/14 (29%)\n80: 4/20 (20%)\n70: 1/7 (14%)\n60: 0/7 (0%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "489fc228-f284-49e5-b485-ae2326d673f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.03,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Supports hypothesis that treating earlier in disease course may enhance efficacy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f164944-0ab7-470d-8513-5f9ffd6a05eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.03,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Predictably, patients with higher PS were more likely to respond to treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0988204-f267-422f-919a-9fcf15f71a83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.35,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Change > 100%, SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR)\nOnly patients with measurable target enhancing lesions at both baseline and post-baseline are included.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a872782c-b1d0-495f-8c64-95b52de387de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "RANO HGG response correlation to performance status (PS) supports early-line trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e61e3b8d-11db-4872-9238-e1158070acab",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "d3043e2d-d02c-4e24-8f69-714f7d3ac3a2",
      "evidence": "chart/waterfall: ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline Glioma",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "7df034ba-8b82-48a9-931a-54c9c4d04f47",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents efficacy data for ONC201 in recurrent H3 K27M DMG",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "77a4ca89-6944-4b59-9557-b7e1ac4d70e5",
      "evidence": "The deck presents data on the unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "Highlight the cost of inaction in treating H3 K27M-mutant diffuse glioma",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}